Scholar Rock Holding Corp 近日就其候选药物 Apitegromab 用于治疗脊髓性肌萎缩症的上市许可申请，提供了欧洲药品管理局人用药品委员会意见发布时间的最新信息。公司表示，正在积极准备相关材料，并期待在既定时间框架内获得监管机构的评估结果。该意见对于后续的上市批准进程至关重要，市场对此保持密切关注。
Scholar Rock Holding Corp 近日就其候选药物 Apitegromab 用于治疗脊髓性肌萎缩症的上市许可申请，提供了欧洲药品管理局人用药品委员会意见发布时间的最新信息。公司表示，正在积极准备相关材料，并期待在既定时间框架内获得监管机构的评估结果。该意见对于后续的上市批准进程至关重要，市场对此保持密切关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.